Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin
NCT00906529 · University of Texas Southwestern Medical Center · PHASE4 · withdrawn · last registry update 2019-01-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, University of Texas Southwestern Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-01-10Phase 3 first posted: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud, Metformin + Insulin Detemir (NCT04222348)
- 2020-01-07Results posted on the registry: Sanofi, Insulin glargine, 300 units per milliliter (U/mL) + Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra) (NCT03260868)
- 2019-12-23Results posted on the registry: Emory University, Sitagliptin + Placebo (NCT02556918)
- 2019-12-12Results posted on the registry: Massachusetts General Hospital, a drug against INSR (NCT01684943)
- 2019-12-06Results posted on the registry: HealthPartners Institute, Insulin glulisine + Saline (NCT02432716)
- 2019-11-27Results posted on the registry: Novo Nordisk A/S, insulin degludec/liraglutide + insulin glargine (NCT02501161)
- 2019-10-22Results posted on the registry: University of Texas Southwestern Medical Center, Metformin + Detemir (NCT01966978)
- 2019-10-11Results posted on the registry: University of Texas Southwestern Medical Center, Insulin detemir + Glargine (NCT00564018)
- 2019-10-11Also stopped (terminated): University of Texas Southwestern Medical Center, Insulin detemir + Glargine (NCT00564018)
- 2019-08-07Results posted on the registry: Indiana University, liraglutide + insulin detemir (NCT01232946)
- 2019-07-29Results posted on the registry: Novo Nordisk A/S, insulin degludec/liraglutide + insulin degludec (NCT02607306)
- 2019-07-23Also stopped (withdrawn): Institut de Recherches Cliniques de Montreal, Insulin + Glucagon (NCT02846857)
- 2019-07-17Phase 3 first posted: Geropharm, Humalog Mix25 + Insulin Lispro Biphasic 25 (NCT04023344)
- 2019-06-03Results posted on the registry: University of Oxford, Linsitinib (NCT02546544)
- 2019-05-16Phase 3 first posted: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03952130)
- 2019-05-16Phase 3 first posted: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03952143)
- 2019-05-01Results posted on the registry: Sanofi, Insulin glargine, 300 U/ml + Insulin glargine, 100 U/ml (NCT02451137)
- 2019-04-04Results posted on the registry: Novo Nordisk A/S, Faster-acting insulin aspart + insulin aspart (NCT02670915)
- 2019-03-20Phase 3 first posted: Eli Lilly and Company, Tirzepatide + Insulin Degludec (NCT03882970)
- 2019-03-20Results posted on the registry: University of Michigan, Insulin treatment for hyperglycemia (NCT01683331)
- 2019-03-15Results posted on the registry: Eli Lilly and Company, Insulin Peglispro + Insulin Glargine (NCT01894568)
- 2019-03-11Results posted on the registry: Novo Nordisk A/S, Insulin degludec/liraglutide + Insulin degludec (NCT02911948)
- 2019-03-11Results posted on the registry: Eli Lilly and Company, Insulin Peglispro + Insulin Glargine (NCT01771250)
- 2019-03-06Results posted on the registry: Eli Lilly and Company, Insulin Peglispro + Human Insulin (NCT02109029)
- 2019-03-05Phase 3 first posted: Population Health Research Institute, IDegLira + insulin degludec (NCT03862716)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision